Predictive Oncology (POAI) Corporate Media Kit

Predictive Oncology , which holds a vast collection of historical and existing outcome data, is positioning itself in multiple markets with unmet clinical needs armed with a significant competitive advan- tage, namely historical data. While others wait for patient outcomes (e.g. one, three and five year survival) Predictive Oncology’s port- folio of comprehensive clinical data such as cancer-specific tumor response to certain drugs, coupled to its bioinformatics and AI plat- form provides a huge head-start. These assets allow the company to build predictive models of tumor drug response and patient out- come. The company’s collaboration with UPMC Magee-Women’s Hospital underscores the significance of this cutting-edge approach, which is investigating how powerful predictive models based on comprehensive multi-omics profiling of the tumor can be used for individualizing the treatment of ovarian cancer.